Centessa Pharmaceuticals PLC - ESG Rating & Company Profile powered by AI
Detailed ESG analysis of Centessa Pharmaceuticals PLC can be reached by signing up for free. Other corporations in the rating peer group for Centessa Pharmaceuticals PLC are displayed below. If you are employed by Centessa Pharmaceuticals PLC and you would like to use your Sustainability aseessment, please get in touch.
Centessa Pharmaceuticals PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1967 | Hospira Inc | 0.3 | Low |
1967 | PRA Health Sciences Inc | 0.3 | Low |
1970 | Centessa Pharmaceuticals PLC | 0.0 | Low |
1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
1970 | CTC Bio Inc | 0.0 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Centessa Pharmaceuticals PLC have an accelerator or VC vehicle to help deliver innovation?
Does Centessa Pharmaceuticals PLC disclose current and historical energy intensity?
Does Centessa Pharmaceuticals PLC report the average age of the workforce?
Does Centessa Pharmaceuticals PLC reference operational or capital allocation in relation to climate change?
Does Centessa Pharmaceuticals PLC disclose its ethnicity pay gap?
Does Centessa Pharmaceuticals PLC disclose cybersecurity risks?
Does Centessa Pharmaceuticals PLC offer flexible work?
Does Centessa Pharmaceuticals PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Centessa Pharmaceuticals PLC disclose the number of employees in R&D functions?
Does Centessa Pharmaceuticals PLC conduct supply chain audits?
Does Centessa Pharmaceuticals PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Centessa Pharmaceuticals PLC conduct 360 degree staff reviews?
Does Centessa Pharmaceuticals PLC disclose the individual responsible for D&I?
Does Centessa Pharmaceuticals PLC disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Centessa Pharmaceuticals PLC disclose current and / or historical scope 2 emissions?
Does Centessa Pharmaceuticals PLC disclose water use targets?
Does Centessa Pharmaceuticals PLC have careers partnerships with academic institutions?
Did Centessa Pharmaceuticals PLC have a product recall in the last two years?
Does Centessa Pharmaceuticals PLC disclose incidents of discrimination?
Does Centessa Pharmaceuticals PLC allow for Work Councils/Collective Agreements to be formed?
Has Centessa Pharmaceuticals PLC issued a profit warning in the past 24 months?
Does Centessa Pharmaceuticals PLC disclose parental leave metrics?
Does Centessa Pharmaceuticals PLC disclose climate scenario or pathway analysis?
Does Centessa Pharmaceuticals PLC disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Centessa Pharmaceuticals PLC disclose the pay ratio of women to men?
Does Centessa Pharmaceuticals PLC support suppliers with sustainability related research and development?
Does Centessa Pharmaceuticals PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Centessa Pharmaceuticals PLC reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Centessa Pharmaceuticals PLC involved in embryonic stem cell research?
Does Centessa Pharmaceuticals PLC disclose GHG and Air Emissions intensity?
Does Centessa Pharmaceuticals PLC disclose its waste policy?
Does Centessa Pharmaceuticals PLC report according to TCFD requirements?
Does Centessa Pharmaceuticals PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Centessa Pharmaceuticals PLC disclose energy use targets?
Does Centessa Pharmaceuticals PLC disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Centessa Pharmaceuticals PLC have a policy relating to cyber security?
Have a different question?
Potential Risks for Centessa Pharmaceuticals PLC
These potential risks are based on the size, segment and geographies of the company.
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.